

Medicare SSP and Commercial Performance Measures

Note: Blue letters = proposed new measure; Red letters = measure proposed for replacement or deletion

ACO #	Measure title	NQF #	Measure steward	Method of data submission	Pediatric	Commercial or Medicaid Measure	#	Provisional Recommendations
Domain: patient/caregiver experience								
ACO-1	CAHPS: Getting timely care, appointments, and information	0005	AHRQ	Survey				
ACO-2	CAHPS: How well your providers communicate	0005	AHRQ	Survey				
ACO-3	CAHPS: Patients' rating of provider	0005	AHRQ	Survey				
ACO-4	CAHPS: Access to specialists	N/A	CMS	Survey				
ACO-5	CAHPS: Health promotion and education	N/A	CMS	Survey				
ACO-6	CAHPS: Shared decision making	N/A	CMS	Survey				
ACO-7	CAHPS: Health status/functional status	N/A	CMS	Survey				

ACO-X	CAHPS: Stewardship of Patient Resources	N/A	CMS	Survey				
Domain: access and availability of care								
	Children and adolescents access to primary care practitioners		NCQA/HEDIS		P	Commercial	2	(none)
	Adults access to preventive/ ambulatory health services					Commercial	1	PH/HD {none}
Domain: care coordination/patient safety								
ACO-8	Risk standardized all condition readmission (new version to be released Spring 2014)	1789 (adapted)	CMS	Claims		<i>Both</i>	3	Y (?)
ACO-9	Ambulatory Sensitive conditions admissions: chronic obstructive pulmonary disease (COPD) or asthma in older adults	0275	AHRQ, PQI-5	Claims				Y (poor)
ACO-X	All-cause unplanned admission for DM		AHRQ, PQI-1?	Claims				Y (poor)

ACO-X	All-cause unplanned admission for heart failure		AHRQ, PQI-8	Claims				Y (poor)
ACO-X	All-cause unplanned admission for multiple chronic conditions		AHRQ, PQI-92?	Claims				Y (?)
ACO-10	Ambulatory sensitive conditions admissions: heart failure (HF)	0277	AHRQ	Claims				(?)
	Ambulatory Sensitive Admissions		Informed by PQI			Commercial	1	PH/HD
	Depression readmission at 12 months				BH			
ACO-11	Percent of primary care physicians who successfully qualify for an EHR program incentive payment	NA	CMS	Claims and EHR Incentive Program Reporting				(?)
ACO-XX	Percent of primary care physicians who successfully meet meaningful use requirements	NA	CMS	Claims and EHR Incentive Program Reporting				

ACO-X	30-day all cause SNF readmission measure							
	% of prescribers that use e-prescribing					Commercial	1	
CARE-1 (ACO-12)	Medication reconciliation	0097	AMA-PCPI/NCQA	QMAT/WI				
CARE-X (ACO-XX)	Documentation of current medications in the medical record		PQRS/EHR					
CARE-2 (ACO-13)	Falls: screening for future fall risk	0101	AMA-PCPI/NCQA	QMAT/WI				
	Adverse event rate – outpatient procedures					Commercial	1	
	Hospital admissions for asthma (adults)	PQI15					0	PH/HD (poor)
	Hospital admissions for asthma (child)				P		0	PH/HD (poor)
	Annual % of asthma patients (ages 2-20) with one or more asthma-related emergency department visits				P	Medicaid	1	PH/HD (none)
	Post-Admission Follow-up:					Medicaid	1	(none)

	Percentage of adults w/ inpatient “medicine” admissions with post-admission follow-up within 7 days of discharge							
	Annual monitoring for persistent medications (roll-up)	0021?				Commercial	1	(none)
	High risk medication					Commercial	1	(none)
Domain: preventive health								
PREV-5 (ACO-20)	Breast cancer screening	NA (0031?)	NCQA	QMAT/WI		Commercial	5	PH/HD (none)
	Cervical cancer screening	0032	NCQA/HEDIS			Commercial	5	PH/HD (none)
	Chlamydia screening in women		NCQA			Both	3	<i>PH/HD?</i> (none)
	Lead screening in children				P	Commercial	2	<i>PH/HD?</i> (none)
	Glaucoma screening					Commercial	1	(none)
PREV-6 (ACO-19)	Colorectal cancer screening	0034	NCQA	QMAT/WI		Commercial	3	PH/HD (none)
	Childhood immunizations				P	Commercial	1	<i>PH/HD?</i>

	DTaP and IPV							
	Childhood immunizations MMR		NCQA/HEDIS		P	Commercial	1	PH/HD? (good?)
	Childhood immunizations VZV		NCQA/HEDIS		P	Commercial	1	PH/HD?
	Childhood immunizations status combo 2, 3, 4				P	Commercial	1	PH/HD?
	Adolescent immunizations Tdap/TD and meningococcal				P	Commercial	2	PH/HD? (good?)
	Adolescent female immunizations HPV				P	Commercial	1	PH/HD? (poor?)
PREV-7 (ACO-14)	Preventive care and screening: influenza immunization	0041	AMA/PCPI	QMAT/WI		Commercial	1	PH/HD? (fair..6%, older adults)
PREV-8 (ACO-15)	Pneumonia vaccination status for older adults	0043	NCQA	QMAT/WI		Commercial	1	PH/HD? (fair..5%)
PREV-9 (ACO-16)	Preventive care and screening: body mass index screening and follow-up	0421	QIP	QMAT/WI				PH/HD (none)
	Adult BMI assessment					Commercial	2	PH/HD

								(none)
	Weight assessment and counseling for nutrition and physical activity for children/adolescents				P	Commercial	1	PH/HD (none)
	Developmental screening in the first three years of life. Three age breakouts (ages 1, 2, and 3)	1448			P	Medicaid	1	(none)
	Well-child visits in the first 15 months of life	1392			P	Both	4	PH/HD? (none)
	Well-child visits in the third, fourth, fifth and sixth years of life				P	Both	4	PH/HD? (none)
	Adolescent well-care visits		NCQA/HEDIS		P	Commercial	2	PH/HD? (none)
PREV-10 (ACO-17)	Preventive care and screening: tobacco use: screening and cessation intervention	0028	AMA/PCPI	QMAT/WI		Commercial	1	PH/HD
PREV-11 (ACO-21)	Preventive care and screening: screening for high blood pressure and follow-	NA	QIP	QMAT/WI				PH/HD

	up documented							
PREV-12 (ACO-18)	Preventive care and screening: screening for clinical depression and follow-up plan	0418	QIP	QMAT/WI	BH			<i>PH/HD?</i>
	Developmental screening in the first three years of life. Three age breakouts (ages 1, 2, and 3)	1448			P	Medicaid	1	(none)
	Well-child visits in the first 15 months of life	1392			P	Both	4	(none)
	Well-child visits in the third, fourth, fifth and sixth years of life				P	Both	4	(none)
	Adolescent well-care visits		NCQA/HEDIS		P	Commercial	2	(none)
	Annual dental visit				P	Both	2	(none) PH/HD
	Prenatal care		NCQA			Commercial	3	<i>PH/HD?</i> (none)
	Frequency of ongoing prenatal care					Commercial	1	<i>PH/HD?</i> (none)

	Post-partum care					Commercial	2	(none)
Domain: at-risk population								
Asthma								
	Use of appropriate medication for people with asthma	0036	NCQA/HEDIS/NQF		P/A	Both	6	PH/HD (none)
	Disease modifying anti-rheumatic drug therapy for rheumatoid arthritis	0054	NCQA/HEDIS/NQF			Commercial	4	(none)
Cancer								
	Colorectal cancer: follow-up after treatment					Commercial	1	PH/HD (none)
Diabetes								
DM-2 (ACO-27)	Diabetes: hemoglobin A1c poor control (>9%)	0059	NCQA	QMAT/WI		Commercial	3	PH/HD
DM-X (ACO-41)	Diabetes foot exam							PH/HD (Fair - 8%)
DM-X (ACO-42)	Diabetes eye exam	0055?	NCQA/HEDIS			Both	5	PH/HD (Fair - 10%)
DM-13 through 17 (ACO-22 through 26)	Diabetes all-or-nothing composite:	0729	MCM	QMAT/WI				PH/HD (none)

	<ul style="list-style-type: none"> ▪High blood pressure control ▪Low density lipoprotein (LDL-C) control ▪Hemoglobin A1c control (<8%) ▪Daily aspirin or antiplatelet medication use for patients with diabetes and ischemic vascular disease ▪Tobacco non-use 					Commercial	2	
						Commercial	3	
						Commercial	3	
	Diabetes treatment, medication for HTN	0546				Commercial	2	(none)
	Diabetes: medical attention for nephropathy	0062				Commercial	2	{none}
	Diabetes: A1C testing	0057	NCQA/HEDIS			Both	3	PH/HD (Fair - 7%)
	Diabetes: A1C testing, pediatric					Commercial	1	(none)

	Diabetes kidney disease monitoring/urine protein screening		NCQA/HEDIS			Commercial	2	
	Comprehensive diabetes care					Commercial	2	PH/HD (none)
	Diabetes: annual lipid profile	0063?	NCQA/HEDIS			Commercial	3	PH/HD (none)
	Diabetes: blood pressure management (<140/80)	0061	NCQA/HEDIS			Commercial	1	PH/HD? (none)
	Diabetes: LDL=>100 & lipid lowering agent use					Commercial	1	PH/HD? (none)
	% of Metformin use for diabetic and pre-diabetic members (UCLA study)		UCLA study			Commercial	1	(none)
	Medication adherence					Commercial	1	(none)
Epilepsy								
	Anticonvulsants: Persistent use with lab monitoring		NCQA/HEDIS			Commercial	3	(none)
	Carbamazepine: Persistent use with					Commercial	2	(none)

	lab monitoring							
	Phenobarbital: Persistent use with lab monitoring					Commercial	2	(none)
	Phenytoin: Persistent use with lab monitoring					Commercial	2	(none)
	Valproic acid: Persistent use with lab monitoring					Commercial	2	(none)
Hypertension								
HTN-2 (ACO-28)	Controlling high blood pressure	0018	NCQA	QMAT/WI		Commercial	3	PH/HD
	HTN: Serum creatinine testing					Commercial	1	(none)
	Diuretics Persistent use with lab monitoring		NCQA/HEDIS			Commercial	3	(none)
	Medication adherence					Commercial	1	(none)
Ischemic stroke								
	Warfarin: PT/INR monitoring					Commercial	1	(none)
Ischemic vascular disease								

IVD-1 (ACO-29)	Ischemic vascular disease: complete lipid panel and LDL control	0075 (73?)	NCQA	QMAT/WI		Commercial	2	PH/HD? (none)
IVD-2 (ACO-30)	Ischemic vascular disease: use of aspirin of another antithrombotic	0068	NCQA	QMAT/WI		Commercial	1	(none)
	MI, CABG, PCI or IVD with complete lipid profile					Both	2	(none)
	LDL \geq 100 and treated with lipid lowering agent, or LDL $<$ 100					Commercial	1	(none)
	LDL-C screening for patients with cardiovascular conditions		NCQA/HEDIS			Commercial	1	(none)
Heart failure								
HF-6 (ACO-31)	Heart failure: beta-blocker therapy for left ventricular systolic dysfunction	0083	AMA/PCPI/ACC/AHA/AMA	QMAT/WI		Commercial	2	PH/HD? (none)
	Heart failure: beta-blocker therapy		ACC/AHA			Commercial	1	PH/HD? (none)
	Digoxin: Persistent use with lab		NCQA/HEDIS			Commercial	3	(none)

	monitoring							
COPD								
	Pharmacotherapy management of COPD exacerbation		NCQA/HEDIS			Commercial	2	(none)
	Use of spirometry testing in the assessment and diagnosis of COPD	0577				Commercial	2	(none)
Coronary artery disease								
CAD-2 (ACO-32)	Coronary artery disease all-or-nothing composite: Lipid Control	0074	AMA/PCPI/ACC/AHA/AMA	QMAT/WI		Commercial	1	PH/HD? (none)
CAD-7 (ACO-33)	Angiotensin-converting enzyme inhibitor or angiotensin receptor blocker (ACE-I/ARB) therapy—diabetes or left ventricular systolic dysfunction	0066	AMA/PCPI/ACC/AHA/AMA	QMAT/WI		Commercial	2	(none)
CAD-X (ACO-43)	Antiplatelet therapy					Commercial	1?	(none)

CAD-X (ACO-44)	Symptom management – CAD pt seen within 12 months for angina symptoms							<i>PH/HD?</i> (none)
CAD-X (ACO-45)	Beta blocker therapy prior MI or LVEF	0070						(none)
	Persistence of Beta blocker therapy after a heart attack	1528? 0071?	NCQA/HEDIS			Commercial	5	(none)
	Lipid lowering drug for LDL>30					Commercial	2	(none)
	ACE-I/ARB: Persistent use with lab monitoring		NCQA/HEDIS			Commercial	3	(none)
	Post-MI use of ACE-I/ARB w/ h/o HTN, DM, or HF		NCQA/HEDIS			Commercial	2	(none)
	Drug-eluting stent: antiplatelet therapy					Commercial	1	(none)
Low Back Pain								
	Use of imaging studies for low back pain	0052	NCQA/HEDIS/ NQF			Commercial	3	(none)
Migraine								

	Migraine: Frequent use of acute meds/ receiving prophylactic meds					Commercial	1	(none)
Osteoporosis								
	Osteoporosis management in women who had a fracture	0053	NCQA/HEDIS/ NQF			Commercial	5	(none)
Otitis Media with Effusion								
	Tympanostomy tube insertion: pediatric hearing test				P	Commercial	1	(none)
Any diagnosis								
	Medication Adherence among members 81 years and older					Commercial	1	(none)
Domain: Behavioral Health (BH)								
ADHD								
	Follow-up care for children prescribed ADHD medication		NCQA/HEDIS/ NQF		P	Commercial	3	(none)
Depression								

	Antidepressant medication management (acute or continuation?)		NCQA/HEDIS/NQF			Commercial	3	<i>PH/HD?</i> (none)
Any Diagnosis								
	Percentage of adults given a new psychiatric diagnoses, and medication, by a PCP who received a follow-up visit within 30 days					Medicaid	1	(none)
	F/U after hospitalization for mental illness, 7 & 30 days					Commercial	1	(none)
	Potentially harmful drug-disease interactions in the...					Commercial	1	(none)
Domain: acute care								
	Avoidance of antibiotic treatment in adults with acute bronchitis	0058	NCQA/HEDIS/NQF			Commercial	3	(none)
	Appropriate testing for children with pharyngitis	0002	NCQA/HEDIS/NQF		P	Commercial	3	(none)
	Appropriate treatment for children with upper	0069	NCQA/HEDIS/NQF		P	Commercial	4	(none)

	respiratory infection							
Domain: Obstetrics								
	Cesarean section rate in singleton low risk deliveries					Commercial	1	(none)
	Episiotomy in vaginal deliveries					Commercial	1	(none)
Resource efficiency								
	Bed days/1000					Commercial	1	(none)
	EOC efficiency index					Commercial	1	(none)
	ER: ambulatory visits /1k members				C, A	Both	3	(none)
	Non-emergent ER visits/1000					Commercial	1	(none)
	% of ER visits Non-emergent					Commercial	1	(none)
	ER repeat visit rate					Commercial	1	(none)
	% of members with 3 or more ER visits					Commercial	1	(none)
	Potentially avoidable ER rate		Custom			Commercial	1	(none)
	Generic dispensing/		Custom?			Commercial	3	

	substitution							
--	--------------	--	--	--	--	--	--	--

*AHRQ = Agency for Healthcare Research and Quality, ACC = American College of Cardiology, AHA = AmericanHeart Association, AMA = American Medical Association, MCM = Minnesota Community Measurement, NCQA = National Committee on Quality Assurance, PCPI = Physician Consortium for Performance Improvement, QIP = Quality Insights of Pennsylvania.

**Italics = Payer appears to use same measure, though potentially with different technical specifications

Note:

- 1) Did not include Cigna “Evidence-based measures”
- 2) One payer appears to track and reward NCQA PCMH recognition or NCQA Bridges to Excellence Condition Specific Recognition Programs
- 3) EOC efficiency index – cost comparison of complete or full year episodes of care against an adjusted average by episode treatment group.